HGSI asks for FDA approval of anthrax drug ABthrax
Associated Press, 05.21.09, 08:00 AM EDT
Human Genome Sciences Inc. [link to board of directors] said Thursday it asked the Food and Drug Administration to approve ABthrax, a drug it is developing to treat inhaled anthrax. Human Genome Sciences submitted a Biologics License Application for ABthrax, or raxibacumab. The company is developing the drug for emergency use, such as a bioterrorist attack. Human Genome Sciences delivered 20,000 doses of the drug to the U.S. Strategic National Stockpile in the first quarter.